FDA tells UniQure study data insufficient for brain disorder therapy application

Group 1 - The FDA has informed UniQure that the data from its early-to-mid stage trial is insufficient to support a marketing application for its gene therapy aimed at treating brain disorders [1] - UniQure's gene therapy is currently under scrutiny, which may impact its future development and commercialization plans [1] Group 2 - BlackRock's Global Infrastructure Partners and EQT AB have agreed to acquire AES Corp for a total of $33.4 billion, including debt [6] - This acquisition reflects ongoing consolidation trends in the energy sector, highlighting the interest of investment firms in utility companies [6]